



#12

Atty. Dkt. No. SALK 2270-5
(088802-5212)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: EVANS, et al.

Title: NOVEL STEROID-ACTIVATED
NUCLEAR RECEPTORS AND USES
THEREFOR

Appl. No.: 10/081,555

Filing Date: February 20, 2002

Examiner: Unknown

Art Unit: Unknown

CERTIFICATE OF MAILING
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on the date below.

GERMAINE SARDI

(Printed Name)

Germaine Sardi

(Signature)

November 19, 2002

(Date of Deposit)

AMENDMENT

Commissioner for Patents
Box Missing Parts
Washington, D.C. 20231

Sir:

In response to the Office communication dated September 20, 2002 (Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures), please consider the following amendments and remarks.

In the Specification

Please replace paragraphs [0061] and [0062] with the following amended paragraphs [0061] and [0062]. A marked-up version of these paragraphs, showing the changes made, is also provided herewith as Appendix A.

-- [0061] Examples of response elements suitable for use in practice of the invention. methods can be selected from the following:

In re application of
Evans et al.
Appl. No. 10/081,555
Page 2

Atty. Dkt. No. SALK 2270-5
(088802-5212)

DR-3,4,5 = AGGTCA n AGGTCA, wherein n is 3, 4, or 5 (SEQ ID NOs: 44, 45 and 46);

β DR-3,4,5 = AGTTCAN n TGAAC t , wherein n is 3, 4 or 5 (SEQ ID NOs: 47, 48 and 22); and

IR-6 = TGAAC t N n AGGTCA, wherein n is 6 (SEQ ID NO: 23), and the like.

[0062] Those of skill in the art will recognize that any combination of nucleotides can be used to make up the 3, 4, 5, or 6 nucleotide space between the repeated half sites (*i.e.*, N n in SEQ ID NOs: 44, 45, 46, 22 or 23). --

Sequence Listing

Applicants respectfully submit a computer readable form (CRF) and a paper copy of the sequence listing herewith. A statement to support filing and submission in accordance with 37 C.F.R. 1.821-1.825 is also enclosed herewith.